Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants With Type 2 Diabetes

Summary

Participation Requirements

Description

This is a single centre Prospective Randomised Open Blinded End-point (PROBE) pilot study designed to understand the role the GLP-1 receptor agonist, exenatide, and glucagon receptor co-agonism has on normal cardiac physiology, myocardial energetics and myocardial glucose utilisation. Overweight par...

This is a single centre Prospective Randomised Open Blinded End-point (PROBE) pilot study designed to understand the role the GLP-1 receptor agonist, exenatide, and glucagon receptor co-agonism has on normal cardiac physiology, myocardial energetics and myocardial glucose utilisation. Overweight participants with type 2 diabetes will act as their own control and will undergo a series of four imaging visits (in a randomised order) as detailed below: Cardiac positron emission tomography-magnetic resonance imaging (PET-MRI) with carbon-11 acetate (11C-acetate) - placebo infusion Cardiac PET-MRI with fluorine-18-fluorodeoxyglucose (18F-FDG) - placebo infusion Cardiac magnetic resonance imaging (CMR) - placebo infusion. Followed by Cardiac PET-MRI 11C-acetate - exenatide and glucagon infusion. Followed by CMR - exenatide and glucagon infusion Cardiac PET-MRI with 18F-FDG - exenatide and glucagon infusion Study outcome measures are detailed below

Tracking Information